These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3055567)

  • 1. Development of malaria vaccines.
    Perrin LH; Simitsek P; Srivastava I
    Trop Geogr Med; 1988 Jul; 40(3):S6-21. PubMed ID: 3055567
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunology and molecular biology: targetting of a vaccine].
    Perrin LH; Mach B
    Ther Umsch; 1986 Feb; 43(2):148-54. PubMed ID: 3515610
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of asexual blood stage malaria vaccines.
    Kidson C
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):391-6. PubMed ID: 3064322
    [No Abstract]   [Full Text] [Related]  

  • 4. Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.
    Cowman AF; Baldi DL; Duraisingh M; Healer J; Mills KE; O'Donnell RA; Thompson J; Triglia T; Wickham ME; Crabb BS
    Philos Trans R Soc Lond B Biol Sci; 2002 Jan; 357(1417):25-33. PubMed ID: 11839179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Merozoite selection of erythrocytes by age and the induction of protective immunity.
    Brown KN; Carlsson J; Jarra W
    Blood Cells; 1990; 16(2-3):313-8. PubMed ID: 2096982
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccines for human malaria: epidemiological and immunological perspectives.
    Webster HK; Diggs CL; Ballou WR; Chulay JD
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):375-89. PubMed ID: 3064321
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunologic prevention of malaria].
    Wagner WH
    Med Monatsschr Pharm; 1990 Jul; 13(7):209-15. PubMed ID: 1695990
    [No Abstract]   [Full Text] [Related]  

  • 8. The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation.
    Good MF; Kumar S; Miller LH
    Immunol Today; 1988 Nov; 9(11):351-5. PubMed ID: 3076406
    [No Abstract]   [Full Text] [Related]  

  • 9. Malaria vaccines. Are they approaching reality?
    Perlmann P
    Nature; 1987 Jul 16-22; 328(6127):205-6. PubMed ID: 3299105
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of protective immunity against experimental infection with malaria using synthetic peptides.
    Patarroyo ME; Romero P; Torres ML; Clavijo P; Moreno A; Martínez A; Rodríguez R; Guzman F; Cabezas E
    Nature; 1987 Aug 13-19; 328(6131):629-32. PubMed ID: 3302727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular strategy for parasitism and vaccine development of falciparum malaria].
    Horii T
    Tanpakushitsu Kakusan Koso; 2001 Dec; 46(15):2154-62. PubMed ID: 11762075
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of asexual erythrocytic malaria vaccines.
    Chulay JD
    Prog Clin Biol Res; 1989; 313():13-21. PubMed ID: 2675112
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
    Ballou WR; Kester KE; Heppner DG
    Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmodium yoelii: experimental evidences for the conserved epitopes between mouse and human malaria parasite, Plasmodium falciparum.
    Xu L; Pei X; Berzins K; Chaudhuri A
    Exp Parasitol; 2007 Jul; 116(3):214-24. PubMed ID: 17336297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.
    Dobaño C; Sedegah M; Rogers WO; Kumar S; Zheng H; Hoffman SL; Doolan DL
    Exp Parasitol; 2009 Jun; 122(2):112-23. PubMed ID: 19249301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunological challenge to developing a vaccine to the blood stages of malaria parasites.
    Good MF; Stanisic D; Xu H; Elliott S; Wykes M
    Immunol Rev; 2004 Oct; 201():254-67. PubMed ID: 15361246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malaria vaccines - The long synthetic peptide approach: Technical and conceptual advancements.
    Olugbile S; Habel C; Servis C; Spertini F; Verdini A; Corradin G
    Curr Opin Mol Ther; 2010 Feb; 12(1):64-76. PubMed ID: 20140818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malaria vaccine research].
    Sellioğlu B
    Mikrobiyol Bul; 1986 Jan; 20(1):37-41. PubMed ID: 3523172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria.
    Luty AJ; Lell B; Schmidt-Ott R; Lehman LG; Luckner D; Greve B; Matousek P; Herbich K; Schmid D; Ulbert S; Migot-Nabias F; Dubois B; Deloron P; Kremsner PG
    Eur Cytokine Netw; 1998 Dec; 9(4):639-46. PubMed ID: 9889408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium falciparum: analysis of the cytoadherence inhibition of the human monoclonal antibody 33G2 and of antibodies reactive with antigen Pf332.
    Iqbal J; Perlmann P; Berzins K
    Exp Parasitol; 1993 Aug; 77(1):79-87. PubMed ID: 8344409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.